Citations

Clear

861 citation(s) found for "Sd, Wexner".

Cardiovascular-Kidney-Metabolic Syndrome: Population and Policy Implications: 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
Brewer, LaPrincess C. , Joseph, Joshua J. , Cooper, Lisa A. , Brewer, LaPrincess C , Joseph, Joshua J

Mayo Clinic

Circulation | July 27, 2026 | Volume: 154 | Issue: 4 | Pages: 405-408

10.1161/circulationaha.126.080897 | PMID 42507769 Get It

Unintentional Weight Loss Does Not Predict Poor Outcomes in Zenker Diverticulum
Allen, Jacqueline , Belafsky, Peter C., deSilva, Brad W. , Dhar, Shumon I. , Ekbom, Dale C. , Friedman, Aaron D. , Fritz, Mark A. , Gardner, Glendon M., Johnson, Christopher, Kasperbauer, Jan L. , Kim, Brandon , Kuhn, Maggie A. , Madden, Lyndsay L., Matrka, Laura , Piraka, Cyrus, Ramaswamy, Apoorva, Rosen, Clark A. , Sibley, Haley , Wright, Carter, Yang, Z. Mike, Young, VyVy N. , Postma, Gregory, Howell, Rebecca J. , Allen, Jacqui , Amin, Milan R , Bayan, Semirra L. , deSilva, Brad , Dhar, Shumon I , Ekbom, Dale , Fritz, Mark , Kasperbauer, Jan , Krekeler, Brittany N , Kuhn, Maggie , Ma, Yue , Matrka, Laura , Mayerhoff, Ross , Rosen, Clark , Sibley, Haley C , Tabangin, Meredith , Young, Vyvy , Howell, Rebecca , Schuman, Ari D. , Altaye, Mekibib , Belafsky, Peter C. , Gardner, Glendon M., Guardiani, Elizabeth , Madden, Lyndsay L. , Mayerhoff, Ross , Piraka, Cyrus , Ramaswamy, Apoorva Tewari , Tabangin, Meredith E. , Postma, Gregory

Mayo Clinic

The Laryngoscope | July 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/lary.70734 | PMID 42470432 Get It

ABSTRACT Objective Weight loss is frequently considered a cardinal presenting symptom for patients with Zenker diverticulum (ZD). We hypothesized that weight loss in patients with cricopharyngeal muscle dysfunction (CPMD), with or without diverticula, was associated with the length of symptoms and size of diverticulum. Methods Prospective, multicenter observational study of CPMD patients with and without diverticula reporting unintentional weight loss (+WL) or no weight loss (−WL) prior to enrollment in the Prospective Outcomes of Cricopharyngeal Hypertonicity (POuCH) database. Complications and symptom response using a patient reported outcome measure, the Eating Assessment Tool (EAT‐10), were compared. Results Of 427 patients, 101 (23.6%) were +WL. Median weight loss was 14 pounds (interquartile range [IQR] 10–25). +WL cohort had a mean age of 71.5 (standard deviation [SD] 11.5) vs. 67.9 in −WL (SD 11.6, p = 0.007). Mean preoperative EAT‐10 score was 24.7 in +WL (SD 9.7) and 14.8 in −WL (SD 8.8, p < 0.0001). Higher preoperative weight loss was associated with higher preoperative EAT‐10 ( p < 0.0001, Spearman's ρ = 0.43). Size of diverticulum was associated with WL ( p = 0.003), but weight loss was highest in both large diverticula and CP bars. Duration of symptoms was not associated with weight loss ( p = 0.30). Postoperative complications in +WL and −WL patients were similar ( p = 0.78). Conclusion Unintentional weight loss is common with ZD. Patients with worse dysphagia are more likely to have more weight loss. Weight loss does not increase with the size of the diverticulum or length of symptoms. Surgery has a similar safety profile with greater improvement in dysphagia in patients reporting weight loss. Level of Evidence 3.
Prognostic Factors in Primary Head and Neck Cutaneous Squamous Cell Carcinoma: A Large‐Scale, Multi‐Institutional Competing‐Risks Analysis
Girardi, Fábio Muradás , Machado, Cristian David Cardona, Wysong, Ashley, Ran, Nina A., Granger, Emily , Koyfman, Shlomo A. , Vidimos, Allison T. , Carr, David R., Shahwan, Kathryn T. , Hirotsu, Kelsey E. , Carter, Joi B., Mangold, Aaron R., Srivastava, Divya, Brodland, David G., Zitelli, John A., Willenbrink, Tyler J., Jambusaria‐Pahlajani, Anokhi , Nijhawan, Rajiv I. , Ruiz, Emily S., Cañueto, Javier , Granger, Emily E , Willenbrink, Tyler J , Wysong, Ashley , Carr, David R., Carucci, John A. , Mangold, Aaron R. , Srivastava, Divya , Zitelli, John A. , Ruiz, Emily S.

Mayo Clinic

Journal of Surgical Oncology | July 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jso.70325 | PMID 42437512 Get It

ABSTRACT Background Current staging systems for head and neck cutaneous squamous cell carcinoma (HNCSCC), such as AJCC8 and BWH, often fail to adequately stratify high‐risk patients, particularly due to the exclusion of important biological and host factors. This study aimed to identify independent prognostic factors for HNCSCC outcomes in the largest multi‐institutional retrospective series to date. Methods De‐identified data from 8,610 primary HNCSCC tumors, treated with curative intent surgery across multiple international centers, were analyzed. Outcomes included local recurrence (LR), locoregional metastasis (LM), distant metastasis (DM), and disease‐specific death (DSD). Multivariable Fine–Gray subdistribution hazard regression models with robust standard errors clustered at the patient level were fitted to generate exploratory hypotheses regarding independent hazard determinants. Results During a median follow‐up of 31.4 months (IQR 14.2–52.8), the cumulative incidence was 3.3% for LR, 2.7% for LM, 0.5% for DM, and 1.2% for DSD. Multivariable analysis confirmed that tumor diameter, poor differentiation, deep invasion, and large‐caliber perineural invasion (LCPNI) were the strongest predictors, being significantly associated with at least three of the four outcomes. Notably, factors currently excluded from or weighted differently in staging systems also proved critical: Immunosuppression was significantly associated with LR (SHR 2.03) and DSD (SHR 1.70); and lymphovascular invasion (LVI) was independently associated with LM (SHR 3.00). Poor differentiation demonstrated high prognostic impact, being a significant predictor for all four endpoints. Conclusion Tumor diameter, poor differentiation, deep invasion, LCPNI, immunosuppression status, and LVI are the most critical independent factors for HNCSCC prognosis. Our multi‐institutional data provide a robust framework for hypothesis generation, highlighting that incorporating host biological features and non‐anatomic variables could significantly refine future staging system discussions.
Comparative risk of postoperative complications in ulcerative colitis patients following preoperative advanced therapies: a network meta-analysis with meta-regression
Hayek, Mohammad Al , Estevinho, María Manuela , Kayal, Maia , Hayek, Osamah Al, Armuzzi, Alessandro , Burisch, Johan, Najah, Qasi , Wexner, Steven D, Loftus, Edward V. , Burisch, Johan , Jairath, V , Loftus, Edward V , Peyrin-Biroulet, Laurent , Danese, Silvio , Elhadi, Muhammed , Magro, F , Kayal, Maia , Jairath, Vipul , Wexner, Steven D , Peyrin‐Biroulet, Laurent , Danese, Silvio , Elhadi, Muhammed , Magro, Fernando

Mayo Clinic

Journal of Crohn's and Colitis | July 10, 2026 | Volume: 20 | Issue: 8 | Pages: No page available

10.1093/ecco-jcc/jjag111 | PMID 42570330 Get It

Abstract Background The expanding use of biologic and small-molecule therapies for ulcerative colitis (UC) has raised concerns regarding perioperative safety. We conducted a network meta-analysis to compare short-term postoperative complications associated with preoperative exposure to these agents in patients undergoing colorectal surgery. Methods We systematically searched PubMed, Web of Science, and the Cochrane Library through September 15, 2025, for cohort studies of adults with UC who were exposed to biologic or small-molecule therapy within 12 weeks prior to surgery. Interventions included biologic therapy, small-molecule therapy, and no biologic or small-molecule therapy (control). The primary outcome was overall postoperative complications at 30 and 90 days. Venous thromboembolism (VTE) was assessed as a key secondary outcome. Random-effects network meta-analysis was performed using risk ratios (RRs) with 95% confidence intervals (CIs). Results Sixteen retrospective cohort studies involving 3235 patients were included. At 30 days, ustekinumab and tofacitinib were associated with lower overall postoperative complication rates than control (RR: 0.29; 95% CI: 0.09-0.96; and RR: 0.66; 95% CI: 0.46-0.96, respectively). Anti-tumor necrosis factor (TNF) therapy was associated with higher complication rates compared with vedolizumab, ustekinumab, and tofacitinib at 30 days (RR: 1.27; 95% CI: 1.00-1.63; RR: 3.67; 95% CI: 1.12-12.03; and RR: 1.61; 95% CI: 1.14-2.27, respectively). At 90 days, anti-TNF therapy was associated with higher complication rates than control (RR 1.20, 95% CI 1.03-1.40), although the 90-day analysis was based on limited data. VTE rates were similar across treatments at both time points. Conclusion Preoperative ustekinumab and tofacitinib were associated with fewer 30-day postoperative complications than control or anti-TNF therapy, while vedolizumab was associated with fewer complications than anti-TNF therapy. At 90 days, anti-TNF therapy was associated with higher complication rates compared with control. These findings, particularly at 90 days based on limited data, should be interpreted with caution and require confirmation in well-designed prospective studies with rigorous adjustment for confounding factors.
Consensus Guidelines for Staging and Surveillance Imaging in Cutaneous Squamous Cell Carcinoma
Kassamali, Bina , Schoenfeld, Jonathan D., Sethi, Rosh, Bakst, R H, Barker, C. A., Bradford, Carol R., Carr, David R., Chandra, Sunandana , Connolly, Karen L., Demer, Addison M. , Doonan, Bently, Emerick, Kevin, Friedman, Ben J. , Gali, Linna L., Galloway, Thomas J., Geiger, Jessica L., Kohen, Laurie, Koyfman, Shlomo, Kumar, Shweta Sharat, Learned, Kim O. , Leitenberger, Justin J., Lilley, Elizabeth J. , Lukens, John N. , Medina, Theresa , Mitra, Devarati , Ozog, David, Pashtan, Itai, Pham, Nancy , Powers, Molly, Srivastava, Divya, Taylor, Charlotte S., Witek, Matthew E. , Wysong, Ashley, Zander, David, Silk, Ann W., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily S., Chen, Michelle , Kumar, Shweta S. , Schoenfeld, Jonathan D. , Barker, Christopher A. , Bhatt, Alok A. , Bradford, Carol R. , Bunch, Paul M. , Carr, David R., Carucci, John A. , Chen, Michelle , Connolly, Karen , Doonan, Bently P. , Emerick, Kevin S. , Friedman, Ben J. , Galloway, Thomas J. , Guenette, Jeffrey P. , Kelly, Hillary R. , Khushalani, Nikhil I. , Kohen, Laurie Linden, Leitenberger, Justin J. , Medina, Theresa M. , Pashtan, Itai , Patel, Vishal Anil , Srivastava, Divya , Swiecicki, Paul Loren , Wysong, Ashley, Silk, Ann Willman , Jambusaria‐Pahlajani, Anokhi , Ruiz, Emily S.

Mayo Clinic

JAMA Dermatology | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1001/jamadermatol.2026.2163 | PMID 42418212 Get It

Importance There is no consensus on staging and surveillance imaging for cutaneous squamous cell carcinoma (CSCC). Although imaging has been shown to affect management, broad recommendations from the National Comprehensive Cancer Network have led to variability in clinical practice. Objective To develop multidisciplinary consensus recommendations on the use of staging and surveillance imaging of localized CSCC. Evidence Review A multidisciplinary expert panel across academic and clinical practice settings convened a Delphi consensus, with 3 iterative survey rounds from January to June 2025. Data were analyzed from February 2025 to January 2026. Eligibility defined by at least 1 to 2 CSCC publications during the previous 5 years, involvement in a relevant clinical trial, experience treating at least 3 patients monthly with CSCC, and/or 5 years or longer of clinical practice. Fifty-four experts were invited and 45 (83%) completed all 3 rounds and were included in the final analysis. Structured Delphi surveys evaluated clinical scenarios, imaging modalities, and surveillance strategies for CSCC. Consensus and near-consensus recommendations were generated, defined as 80% or greater and 70% to 79% agreement, respectively. Findings The 45 participants (21 female individuals [47%] and 24 male individuals [53%]; 14 Asian individuals [31%], 1 multiracial individual [2%], and 30 White individuals [67%]) consisted of dermatology (15 [33%]), medical oncology (7 [16%]), radiation oncology (9 [20%]), radiology (9 [20%]), surgery (3 [7%]), and otolaryngology specialists (2 [4%]). The Delphi panel recommended staging and surveillance for CSCCs with at least a 15% risk of metastasis. Consensus or near consensus was reached to recommend staging and surveillance imaging for tumors with a concern for metastasis, bone invasion, invasion beyond subcutaneous fat, large-caliber nerve invasion, or a diameter of 4 cm or larger or the combination of tumors with poorly differentiated histology and any of the following: diameter of 2 cm or larger, lymphovascular invasion and subcutaneous fat invasion, or lymphovascular invasion and small-caliber perineural invasion. Computed tomography imaging was the preferred modality for nodal staging (38 [84%]) and surveillance (35 [78%]). For surveillance duration, consensus was reached to provide imaging for at least 2 years, and near consensus was reached for at least 3 years. Conclusions and Relevance This study provides an expert consensus–based framework to standardize imaging in localized CSCC that may inform future guidelines.
Adult Chronic Pancreatitis Working Group: Goals, Accomplishments and the Path Ahead. A Report From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer
Yadav, Dhiraj, Andersen, Dana K., Bellin, Melena D., Fisher, Willian, Fogel, Evan L., Forsmark, Christopher E., Hart, Phil A., Lee, Bomi, Palermo, Tonya, Pandol, Stephen J., Park, Walter G., Saloman, Jami, Serrano, Jose, Tirkes, Temel, Topazian, Mark D., Eeden, Stephen van Den, Vege, Santhi Swaroop, Conwell, Darwin L., Lee, Bomi , Park, Walter G. , Yadav, Dhiraj, Li, Liang, Andersen, Dana K. , Bellin, Melena D. , Cruz‐Monserrate, Zobeida , Fogel, Evan L. , Forsmark, Chris E. , Hart, Phil A. , Palermo, Tonya, Pandol, Stephen J , Park, Walter G., Saloman, Jami L. , Serrano, José , Tirkes, Temel , Topazian, Mark , Van Den Eeden, Stephen K , Vege, Santhi Swaroop , Conwell, Darwin L.

Mayo Clinic

Pancreas | June 25, 2026 | Volume: 55 | Issue: 7 | Pages: e791-e800

10.1097/mpa.0000000000002657 | PMID 42348838 Get It

The adult chronic pancreatitis (CP) working group, formed at the inception of the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC), has developed a robust framework and infrastructure to conduct clinical, translational, and mechanistic studies of CP. At its core is PRO spective Evaluation of C hronic Pancreatitis for E pid E miologic and Translational Stu D ies (PROCEED), the first longitudinal cohort study of CP in US adults, launched in 2017. PROCEED has developed a well-annotated clinical data set of over 2000 deeply-phenotyped participants, a biorepository and an imaging repository. Investigators have published promising data on blood-based and imaging-based biomarkers of CP diagnosis and pain, which are awaiting validation. Clinical observations include classification of patients into mechanism-based pain phenotypes using responses to PROMIS questionnaires, prevalence and predictors of opioid use, prevalence of psychological comorbidity, and osteopathy in CP patients. Pilot clinical trials have evaluated the effect of oral indomethacin on pancreatic fluid prostaglandin E2 levels and Internet-based cognitive behavioral therapy (CBT) for chronic pain. Results of pilot trials have led to an ongoing definitive randomized clinical trial for CBT. The rich environment and resources have facilitated mentorship and academic development of many early-stage investigators. Investigators outside of the consortium have opportunities for collaboration. In the next 5 years, the working group plans to further strengthen the research platform, complete primary and key secondary analyses of PROCEED and ancillary studies, continue efforts to develop biomarkers for diagnosis and prognosis of CP, and complete ongoing clinical trials to address unanswered questions in the field.
Deep learning based time series analysis for breathing phase prediction in phase-gated proton therapy
Qian, J. , Tang, Xueyan , Matysiak, Witold, Zhou, Mi , Stottler, Zachary Shaun, El‐Sherif, Omar , Deisher, Amanda, Tryggestad, E., Matysiak, W , Qian, Jing , Matysiak, Witold P , Stottler, Zachary S, Deisher, Amanda J, Tryggestad, Erik, Zhou, Mi , El-Sherif, Omar

Mayo Clinic

Physics in Medicine & Biology | June 17, 2026 | Volume: 71 | Issue: 13 | Pages: 135005

10.1088/1361-6560/ae7eec | PMID 42309140 Get It

Abstract Objective . Phase gating is a critical technique to mitigate tumor motion during radiotherapy, particularly in spot-scanned particle therapy where internal motion can interfere with dynamic spot scanning patterns and, simultaneously, introducing substantial range uncertainties. However, the current commercial state of the art in real-time phase prediction is challenged by patient-specific breathing variability as well as detection and delivery system latencies. This leads to suboptimal efficiency, mis-timed radiation delivery and requires frequent manual intervention. This study aims to improve phase prediction accuracy using deep learning (DL)-based time series forecasting to enable more accurate dose delivery. Approach . Retrospective breathing waveforms from 69 proton therapy patients, sampled at 30 Hz, were labeled with inspiratory peaks and assigned subjective regularity scores (four levels). DL models with various architectures were trained using waveform amplitude to predict current or future breathing phases. Model performance was evaluated using mean squared error, phase binning accuracy, and timing deviation for radiation on/off events. Bayesian optimization was used for hyperparameter tuning. Results were compared between models and against a commercial algorithm currently in clinical use. Main Results . The curated waveform dataset included 165 242 s for training, 24 057 s for validation, and 30 322 s for testing, with an additional 40 604 s from separate patients for extended validation. The long short-term memory and temporal fusion transformer models significantly outperformed the commercial algorithm, improving phase prediction accuracy by nearly 20% and reducing timing deviations across all regularity levels. Significance . DL-based time series forecasting may substantially improve breathing phase prediction accuracy over current clinically available methods, offering a more precise and reliable approach to phase-gated radiation delivery.
Volume-Staged Stereotactic Radiosurgery in Pediatric Patients With Large Brain Arteriovenous Malformations: An International, Multicenter Study
Hajikarimloo, Bardia , Tos, Salem M., Ferguson, Robert , Chan, Jason W., Sneed, Penny K. , McDermott, Michael W., Seymour, Zachary , Grills, Inga, Reda, Wael A., Tawadros, Sameh R., Abdelkarim, Khaled, Emad, Reem M. , Lunsford, L. Dade, Niranjan, Ajay, Peker, S A, Samanci, Yavuz, Lee, Cheng-chia, Yang, Huai-che, Sheehan, Darrah, Sheehan, Kimball, Liscak, Roman, Chytka, Tomáš , Alzate, Juan, Kondziolka, Douglas, Moreno, Nuria Martínez , Álvarez, Roberto Martínez , Hallan, David R , Fritch, Chanju, Jareczek, Francis J., Sciscent, Bao Y., Mathieu, David, Carrier, Louis, Abdelsalam, Ahmed, Starke, Robert M., BENJAMIN, CAROLINA, Almeida, Timoteo, Singh, S.P., Lazo, Erwin, Chen, C Y, Esquenazi, Yoshua, Becerril-Gaitan, Andrea, Blanco, Angel I., Palmer, Joshua D., Picozzi, Piero, Lanterna, Luigi Alberto Andrea, Bowden, Greg N., Peterson, Jennifer L., Chiang, Veronica , Pikis, Stylianos , Sheehan, Jason P. , Sheehan, Jason , Tos, Salem M , Mantziaris, Georgios , Shinya, Yuki , Chan, Jason , McDermott, Michael W. , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , El-Shehaby, Amr M. N. , Bin-Alamer, Othman , Lunsford, L. Dade , Niranjan, Ajay , Peker, Selçuk , Samancı, Yavuz , Lee, Cheng-chia, Yang, Huai‐Che , Sheehan, Darrah, Sheehan, Kimball , Liščák, Roman , Alzate, Juan Diego , Kondziolka, Douglas, Meng, Ying , Fritch, Chanju , Jareczek, Francis J. , Sciscent, Bao Y. , Mathieu, David , Abdelsalam, Ahmed , Starke, Robert M. , Almeida, Timóteo , Tripathi, Manjul , Speckter, Herwin , Lazo, Erwin , Esquenazi, Yoshua , Becerril‐Gaitan, Andrea , Amsbaugh, Mark J. , Upadhyay, Rituraj , Palmer, Joshua D. , Franzini, Andrea , Picozzi, Piero , Lanterna, Andrea Luigi, Bowden, Greg , Warnick, Ronald E.

Mayo Clinic

Neurosurgery | June 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004136 | PMID 42300133 Get It

BACKGROUND AND OBJECTIVES: Pediatric large-volume brain arteriovenous malformations (AVMs) carry a substantial lifelong hemorrhage risk, neurological symptoms, and treatment morbidity. Single-session stereotactic radiosurgery (SRS) is often unsuitable due to constraints on dose-volume toxicity. Volume-staged SRS (VS-SRS) enables sequential dosing of large nidus volumes, potentially enhancing safety while maintaining efficacy. Evidence in children remains limited. We aimed to evaluate outcomes of VS-SRS for large AVMs in pediatric patients. METHODS: A multicenter retrospective cohort was assembled from 21 centers, including patients aged younger than 21 years treated with VS-SRS for AVMs >10 cm 3 . Clinical and radiological end points included obliteration, hemorrhage, and permanent symptomatic radiation-induced changes (RIC). RESULTS: A total of 103 patients were included (median age 14 years; IQR, 12-17). The median nidus volume at first stage was 18.2 cm 3 (IQR, 12.3-25.6). Median prescription dose per stage was 17 Gy (IQR, 16-18). The median clinical follow-up from the first stage was 57.5 months (IQR, 25-138). Obliteration occurred in 42 of 103 patients (40.8%), with actuarial rates of 6.9% (95% CI: 2.8-14) at 3 years and 29% (95% CI: 20-39) at 5 years. Hemorrhage occurred in 17 of 103 patients (16.5%) during follow-up, and permanent RIC was observed in 9 of 103 patients (8.7%). CONCLUSION: VS-SRS is a reasonably safe, selected option for pediatric large-volume AVMs when microsurgical or endovascular cure is not feasible or prudent. Delivering ≥17 Gy per stage while limiting each treatment volume to <15 cm 3 supports durable nidus control with acceptable toxicity. VS-SRS represents a key modality in multidisciplinary management of this historically difficult-to-treat population.
Recommendation Statement for the Validation, Implementation, and Clinical Application of Artificial Intelligence Within a Clinical Laboratory from the Digital Pathology Association
Silberman, Nathan , Parwani, Anil, McClintock, David S. , Lujan, Giovanni, Garcia, Christopher, Hanna, Matthew G., Pantanowitz, Liron, Lennerz, Jochen K., SHOWALTER, TIMOTHY, Gerrard, Paul, Parwani, Anil Vasdev , Lujan, Giovanni Mario , Gondim, Dibson , Hanna, Matthew G., Pantanowitz, Liron , Showalter, Timothy N.

Mayo Clinic

AI in Precision Oncology | June 11, 2026 | Volume: 3 | Issue: 4 | Pages: 71-97

10.1177/2993091x261455975 Get It

Background: The rapid adoption of digital pathology and artificial intelligence (AI) in oncology creates multiple opportunities for precision diagnostics but also creates an urgent need for evidence-based standards to ensure safe and effective implementation. Goal: This article, developed by the Digital Pathology Association, presents recommendations for digital pathology as well as the validation and clinical utility of AI-enabled digital pathology tools in clinical practice. This guidance addresses analytical and clinical validation, algorithm reliability, and criteria for establishing clinical utility attributed to test use. Key recommendations emphasize separate validation of scanning processes and AI algorithms, concordance studies to support interscanner generalizability, rigorous assessment of accuracy and reliability in real-world settings, and clear description of algorithmic use limitations. These recommendations further provide frameworks for when AI may replace or augment existing diagnostic approaches, such as biomarker scoring, cancer diagnosis, and prognostic risk assessment. Conclusions: By considering payer, regulatory, and clinical perspectives, the recommendations promote transparency, trust, and reproducibility in digital pathology while encouraging value-based care delivery. We support responsible innovation in computational pathology, ensuring that AI applications achieve not only technical performance goals but also deliver measurable clinical benefit to patients.